{
  "metadata": {
    "description": "Vendor-published Medicare coverage information for OpenOnco tests",
    "lastUpdated": "2026-01-12",
    "sources": "Vendor websites, press releases, billing pages",
    "summary": {
      "totalVendors": 17,
      "totalTests": 41,
      "vendorsPendingResearch": 0
    }
  },
  "vendors": {
    "Natera": {
      "billingPage": "https://www.natera.com/oncology/billing/",
      "tests": {
        "Signatera": {
          "lcd": "L38779",
          "lcdName": "MolDX: Molecular Residual Disease Testing for Cancer",
          "coveredIndications": [
            "Stage II-IV colorectal cancer",
            "Stage II-IV breast cancer",
            "Stage II-IV bladder cancer",
            "Stage II-IV ovarian cancer",
            "Stage I-IV NSCLC",
            "Pan-cancer immunotherapy monitoring"
          ],
          "reimbursement": null,
          "pressReleases": [
            { "date": "2025-06", "title": "Signatera Genome LCD coverage" },
            { "date": "2023-05", "title": "Pan-cancer immunotherapy coverage" }
          ]
        },
        "Signatera Genome": {
          "lcd": "L38779",
          "lcdName": "MolDX: Molecular Residual Disease Testing for Cancer",
          "coveredIndications": ["Same as Signatera"],
          "reimbursement": null
        },
        "Foresight CLARITY Lymphoma": {
          "lcd": null,
          "lcdName": null,
          "coveredIndications": [],
          "reimbursement": null,
          "notes": "Need to verify coverage status"
        }
      }
    },
    "Guardant Health": {
      "billingPage": "https://guardanthealth.com/billing-support/",
      "tests": {
        "Guardant360 CDx": {
          "ncd": "90.2",
          "ncdName": "Next Generation Sequencing (NGS)",
          "article": "A56148",
          "coveredIndications": [
            "Recurrent, relapsed, refractory, metastatic, or advanced non-CNS solid tumors",
            "When tissue insufficient or unavailable"
          ],
          "reimbursement": null
        },
        "Guardant360 Liquid": {
          "ncd": "90.2",
          "coveredIndications": ["Same as Guardant360 CDx"],
          "reimbursement": null
        },
        "Guardant360 Response": {
          "lcd": "Treatment Response Monitoring",
          "coveredIndications": [
            "Metastatic/inoperable solid tumors on immune checkpoint inhibitors",
            "Baseline test + follow-up 4-10 weeks post-therapy"
          ],
          "reimbursement": "$3,500"
        },
        "Reveal MRD": {
          "lcd": "L38779",
          "coveredIndications": [
            "Stage II-III colorectal cancer",
            "Within 3 months post-curative intent therapy"
          ],
          "reimbursement": null
        },
        "Shield": {
          "ncd": "210.3",
          "ncdName": "Colorectal Cancer Screening Tests",
          "ncdSection": "B.3 Blood-based Biomarker Tests",
          "coveredIndications": [
            "Age 45-85",
            "Average risk, asymptomatic",
            "Once every 3 years"
          ],
          "reimbursement": "$1,495",
          "notes": "First FDA-approved blood test for CRC screening. ADLT status April 2025."
        },
        "Shield MCD": {
          "lcd": null,
          "coveredIndications": [],
          "notes": "Multi-cancer detection - coverage TBD pending FDA approval"
        }
      }
    },
    "Foundation Medicine": {
      "billingPage": "https://www.foundationmedicine.com/resource/billing-and-financial-assistance",
      "tests": {
        "FoundationOne CDx": {
          "ncd": "90.2",
          "ncdName": "Next Generation Sequencing (NGS)",
          "ncdSection": "Section B (FDA CDx)",
          "coveredIndications": [
            "All solid tumors",
            "Treatment selection",
            "Clinical trial matching"
          ],
          "reimbursement": "97% of Medicare patients have $0 financial responsibility",
          "notes": "First FDA-approved CGP meeting NCD 90.2 requirements"
        },
        "FoundationOne Liquid CDx": {
          "ncd": "90.2",
          "ncdName": "Next Generation Sequencing (NGS)",
          "coveredIndications": [
            "Advanced solid tumors when tissue insufficient"
          ],
          "reimbursement": null
        },
        "FoundationOne Heme": {
          "ncd": "90.2",
          "coveredIndications": [
            "Hematologic malignancies",
            "Sarcomas"
          ],
          "reimbursement": null
        },
        "FoundationOne Tracker (MRD)": {
          "lcd": "L38779",
          "coveredIndications": [],
          "notes": "Partnership with Natera - uses Signatera platform"
        }
      }
    },
    "GRAIL": {
      "billingPage": "https://grail.com/galleri-test/",
      "tests": {
        "Galleri": {
          "ncd": null,
          "lcd": null,
          "coveredIndications": [],
          "reimbursement": "$949 (self-pay)",
          "notes": "NOT covered by Medicare. REACH study (IDE) provides coverage for 50,000 study participants only. Pending FDA approval and congressional action (H.R. 2407, S. 2085)."
        }
      }
    },
    "Exact Sciences": {
      "billingPage": "https://www.exactsciences.com/",
      "tests": {
        "Cologuard Plus": {
          "ncd": null,
          "lcd": null,
          "coveredIndications": [],
          "notes": "Need to verify coverage - different from original Cologuard"
        },
        "Oncoguard Liver": {
          "lcd": null,
          "coveredIndications": [],
          "notes": "Need to verify coverage status"
        },
        "Cancerguard": {
          "lcd": null,
          "coveredIndications": [],
          "notes": "MCED - likely no current coverage"
        },
        "Oncodetect": {
          "lcd": "L38779",
          "coveredIndications": [],
          "notes": "MRD test - likely covered under L38779"
        },
        "OncoExTra": {
          "ncd": "90.2",
          "coveredIndications": [],
          "notes": "CGP test - likely covered under NCD 90.2"
        },
        "Oncotype DX Breast Recurrence Score": {
          "lcd": null,
          "coveredIndications": ["HR+, HER2-, node-negative early breast cancer"],
          "reimbursement": "Covered",
          "notes": "Well-established test with broad coverage"
        }
      }
    },
    "Tempus AI": {
      "billingPage": "https://www.tempus.com/",
      "tests": {
        "Tempus xT CDx": {
          "ncd": "90.2",
          "ncdName": "Next Generation Sequencing (NGS)",
          "lcd": null,
          "cptCode": "81479",
          "coveredIndications": [
            "Solid tumor profiling",
            "Colorectal cancer (companion diagnostic for KRAS)",
            "All solid malignant neoplasms"
          ],
          "reimbursement": null,
          "notes": "FDA PMA approved May 2023. CMS added to NCD 90.2 coverage Nov 2023 (transmittal 13278). 648-gene panel."
        },
        "Tempus xT": {
          "ncd": null,
          "lcd": "MolDX",
          "cptCode": "81479",
          "coveredIndications": [
            "All solid tumors (tumor-only or normal-matched)",
            "Myeloid malignancies",
            "Suspected myeloid malignancies"
          ],
          "reimbursement": null,
          "notes": "LDT version. Medicare coverage announced Nov 2023 via MolDX/Palmetto GBA."
        },
        "Tempus xF": {
          "ncd": null,
          "lcd": "L38043",
          "coveredIndications": ["Liquid biopsy CGP"],
          "notes": "Liquid biopsy panel - likely covered under plasma genomic profiling LCD"
        }
      }
    },
    "Caris Life Sciences": {
      "billingPage": "https://www.carislifesciences.com/patients/patient-services/financial-services/",
      "tests": {
        "MI Cancer Seek": {
          "ncd": "90.2",
          "ncdName": "Next Generation Sequencing (NGS)",
          "cptCode": "0211U",
          "coveredIndications": [
            "All solid tumors",
            "WES/WTS analysis"
          ],
          "reimbursement": "$8,455",
          "notes": "FDA PMA approved Nov 2024. First WES/WTS CDx. PLA code 0211U."
        },
        "MI Profile": {
          "lcd": "L38121",
          "lcdName": "MolDX: NGS for Solid Tumors",
          "cptCode": "81479",
          "coveredIndications": [
            "All solid tumors",
            "Includes MI Cancer Seek + IHC + additional markers"
          ],
          "reimbursement": null,
          "notes": "Full molecular profiling package. Uses MI Cancer Seek for NGS component if specimen qualifies, otherwise MI Tumor Seek Hybrid (LDT)."
        },
        "MI Tumor Seek Hybrid": {
          "lcd": "L38121",
          "lcdName": "MolDX: NGS for Solid Tumors",
          "cptCode": "81479",
          "coveredIndications": ["All solid tumors"],
          "notes": "WES/WTS LDT - used when specimen doesn't meet MI Cancer Seek FDA CDx requirements"
        },
        "Caris Assure": {
          "lcd": "MolDX",
          "coveredIndications": ["Liquid biopsy therapy selection"],
          "reimbursement": "$3,649",
          "notes": "Liquid biopsy for treatment decision support. MolDX pricing per Caris IPO filing."
        }
      }
    },
    "Adaptive Biotechnologies": {
      "billingPage": "https://www.clonoseq.com/",
      "tests": {
        "clonoSEQ": {
          "lcd": "L38779",
          "lcdName": "MolDX: Minimal Residual Disease Testing for Cancer",
          "fdaStatus": "FDA De Novo cleared (first MRD IVD)",
          "coveredIndications": [
            "B-cell acute lymphoblastic leukemia (B-ALL) - bone marrow",
            "Multiple myeloma (MM) - bone marrow",
            "Chronic lymphocytic leukemia (CLL) - blood or bone marrow",
            "Diffuse large B-cell lymphoma (DLBCL) - ctDNA/blood (July 2022)",
            "Mantle cell lymphoma (MCL) - MRD monitoring (Nov 2024)",
            "MCL surveillance - single timepoint every 6 months for 5 years (April 2025)"
          ],
          "reimbursement": "Episode payment structure for series of tests",
          "notes": "First and only FDA-cleared MRD assay. Over 240 million covered lives. Coverage via MolDX LCD finalized Nov 2021.",
          "pressReleases": [
            {"date": "2019-01", "title": "Initial Medicare coverage for MM and ALL"},
            {"date": "2020-02", "title": "Expanded coverage for CLL"},
            {"date": "2021-11", "title": "LCD finalized for MRD testing"},
            {"date": "2022-07", "title": "DLBCL coverage (first ctDNA-based)"},
            {"date": "2024-11", "title": "MCL coverage"},
            {"date": "2025-04", "title": "MCL surveillance coverage"}
          ]
        }
      }
    },
    "NeoGenomics": {
      "billingPage": "https://neogenomics.com/pharma-services/testing-services/liquid-biopsy",
      "tests": {
        "RaDaR": {
          "lcd": "L38779",
          "lcdName": "MolDX: Minimal Residual Disease Testing for Cancer",
          "fdaStatus": "FDA Breakthrough Device Designation",
          "coveredIndications": [
            "HR+/HER2- breast cancer (stage II/III, 5+ years post-diagnosis, NED)"
          ],
          "notes": "MolDX coverage announced July 2023, effective March 24, 2023. Tumor-informed, tracks up to 48 variants. LOD 0.001%. Coverage currently breast cancer only - CRC coverage in development.",
          "pressReleases": [
            {"date": "2023-07", "title": "Medicare coverage for HR+/HER2- breast cancer MRD"}
          ]
        },
        "InVisionFirst-Lung": {
          "lcd": "L37870",
          "lcdName": "MolDX: InVisionFirst-Lung Liquid Biopsy",
          "coveredIndications": ["Advanced NSCLC"],
          "notes": "Liquid biopsy for NSCLC therapy selection. Built on InVision platform."
        }
      }
    },
    "Personalis": {
      "billingPage": "https://www.personalis.com/",
      "tests": {
        "NeXT Dx": {
          "lcd": "L38119",
          "lcdName": "MolDX: Next-Generation Sequencing for Solid Tumors",
          "cptCode": "81479",
          "coveredIndications": [
            "All solid tumors",
            "WES/WTS comprehensive profiling"
          ],
          "notes": "Medicare coverage announced Oct 2024, effective Aug 29, 2023. Whole exome + transcriptome with tumor/normal paired analysis.",
          "pressReleases": [
            {"date": "2024-10", "title": "Medicare coverage for NeXT Dx comprehensive profiling"}
          ]
        },
        "NeXT Personal Dx": {
          "lcd": "L38779",
          "lcdName": "MolDX: Minimal Residual Disease Testing for Cancer",
          "coveredIndications": [
            "Stage II and III breast cancer (HR+/HER2-, HER2+, TNBC)",
            "Post-treatment surveillance up to 6 years"
          ],
          "reimbursement": {
            "breastMRDMonitoring": "$4,266 (once per diagnosis)",
            "singlePlasmaTest": "$1,164 (up to 6 years post-treatment)"
          },
          "notes": "Medicare coverage announced Nov 2025, effective Oct 7, 2025. Ultrasensitive WGS-based MRD. Updated reimbursement rates effective Dec 1, 2025. Marketed through Tempus AI partnership.",
          "pressReleases": [
            {"date": "2025-11", "title": "Medicare coverage for breast cancer MRD surveillance"},
            {"date": "2025-11", "title": "Revised reimbursement rates ($4,266/$1,164)"}
          ]
        }
      }
    },
    "BillionToOne": {
      "billingPage": "https://www.northstaronc.com/",
      "tests": {
        "Northstar Select": {
          "lcd": "L38043",
          "lcdName": "MolDX: Plasma-Based Genomic Profiling",
          "coveredIndications": [
            "Advanced solid tumors",
            "Therapy selection"
          ],
          "notes": "Medicare coverage announced April 2025, effective Feb 14, 2025. 84-gene liquid biopsy panel with QCT technology. Head-to-head study showed 51% more actionable alterations vs competitors. LOD 0.15% VAF.",
          "pressReleases": [
            {"date": "2025-04", "title": "Medicare coverage via MolDX L38043"}
          ]
        },
        "Northstar Response": {
          "lcd": null,
          "coveredIndications": ["Treatment response monitoring in advanced cancers"],
          "notes": "NOT YET COVERED. Methylation-based tissue-free TRM test. Company targeting Medicare coverage before end of 2026 per Q3 2025 earnings call.",
          "status": "PENDING_COVERAGE"
        }
      }
    },
    "Memorial Sloan Kettering": {
      "billingPage": "https://www.mskcc.org/insurance-assistance",
      "tests": {
        "MSK-IMPACT": {
          "ncd": "90.2",
          "ncdName": "Next Generation Sequencing (NGS)",
          "ncdSection": "Section D (non-CDx)",
          "fdaStatus": "FDA De Novo Class II authorized (November 2017)",
          "genesAnalyzed": 468,
          "coveredIndications": [
            "Solid malignant neoplasms",
            "Detection of somatic mutations (point mutations, small indels)",
            "Microsatellite instability (MSI)"
          ],
          "coverageNotes": "FDA authorized but NOT a companion diagnostic - covered under NCD 90.2 Section D as lab-developed test. First NGS tumor profiling test to receive FDA authorization through de novo pathway. MSK pursuing CDx status for specific biomarkers to achieve Section A/B coverage.",
          "notes": "468-gene panel, tissue-based (FFPE), includes tumor/normal paired analysis. Available only at MSK. Used for clinical trial enrollment matching. MSK-IMPACT Heme also available for hematologic malignancies."
        },
        "MSK-ACCESS": {
          "ncd": null,
          "lcd": "L38043",
          "lcdName": "MolDX: Plasma-Based Genomic Profiling",
          "coveredIndications": ["Liquid biopsy CGP for solid tumors"],
          "notes": "MSK's liquid biopsy companion to MSK-IMPACT. 129-gene ctDNA panel. Coverage via MolDX plasma genomic profiling LCD."
        }
      }
    },
    "Labcorp": {
      "billingPage": "https://www.labcorp.com/patients/patient-billing",
      "tests": {
        "Invitae PCM (cfDNA MRD)": {
          "lcd": "L38779",
          "lcdName": "MolDX: Minimal Residual Disease Testing for Cancer",
          "coveredIndications": [
            "MRD monitoring",
            "ctDNA-based surveillance"
          ],
          "notes": "Labcorp acquired Invitae's oncology business. Personalized cancer monitoring via cfDNA. Tumor-informed approach."
        }
      }
    },
    "Quest Diagnostics": {
      "billingPage": "https://www.questdiagnostics.com/patients/billing",
      "tests": {
        "Haystack MRD": {
          "lcd": "L38779",
          "lcdName": "MolDX: Minimal Residual Disease Testing for Cancer",
          "coveredIndications": [
            "Multi-solid tumor MRD",
            "Post-treatment surveillance"
          ],
          "notes": "Tumor-informed WGS-derived panel (~50 variants). LOD 6 ppm. Submitted for MolDX coverage. Coverage status: Pending formal announcement but expected covered under L38779."
        }
      }
    },
    "Strata Oncology": {
      "billingPage": "https://strataoncology.com/",
      "tests": {
        "StrataNGS": {
          "lcd": "L38043",
          "lcdName": "MolDX: Plasma-Based Genomic Profiling",
          "coveredIndications": ["Advanced solid tumors", "Therapy selection"],
          "notes": "Liquid biopsy CGP panel. 55 genes for therapy selection. Coverage via MolDX plasma genomic profiling LCD."
        }
      }
    }
  },
  "coveragePolicies": {
    "L38779": {
      "name": "MolDX: Molecular Residual Disease Testing for Cancer",
      "type": "LCD",
      "category": "MRD",
      "mac": "Multiple (Palmetto GBA administered)",
      "generalCriteria": [
        "Stage II-IV solid tumors",
        "Post-curative intent therapy",
        "Serial monitoring for recurrence"
      ]
    },
    "NCD90.2": {
      "documentId": 372,
      "name": "Next Generation Sequencing (NGS)",
      "type": "NCD",
      "category": "CGP/TDS",
      "sections": {
        "B": "FDA-approved companion diagnostics - nationally covered",
        "D": "Laboratory developed tests - MAC discretion"
      }
    },
    "NCD210.3": {
      "name": "Colorectal Cancer Screening Tests",
      "type": "NCD",
      "category": "ECD",
      "sections": {
        "B.3": "Blood-based Biomarker Tests"
      },
      "criteria": [
        "FDA market authorization required",
        "Sensitivity ≥74%",
        "Specificity ≥90%",
        "Age 45-85, average risk"
      ]
    },
    "L38043": {
      "name": "MolDX: Plasma-Based Genomic Profiling",
      "type": "LCD",
      "category": "CGP liquid biopsy"
    },
    "L38121": {
      "name": "MolDX: Next-Generation Sequencing for Solid Tumors",
      "type": "LCD",
      "category": "CGP/TDS",
      "mac": "Noridian J-F (AK, ID, OR, WA, UT, AZ, MT, ND, SD, WY)",
      "generalCriteria": [
        "Advanced solid tumors",
        "Treatment selection decisions",
        "Must pass MolDX technical assessment"
      ]
    }
  },
  "vendorsToResearch": []
}
